Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Gains from Sales and Divestitures (2021 - 2025)

Historic Gains from Sales and Divestitures for iBio (IBIO) over the last 5 years, with Q2 2025 value amounting to $35369.0.

  • iBio's Gains from Sales and Divestitures fell 1589.62% to $35369.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $35369.0, marking a year-over-year decrease of 1589.62%. This contributed to the annual value of $35369.0 for FY2025, which is 1589.62% down from last year.
  • As of Q2 2025, iBio's Gains from Sales and Divestitures stood at $35369.0, which was down 1589.62% from $11575.0 recorded in Q1 2025.
  • In the past 5 years, iBio's Gains from Sales and Divestitures registered a high of $105027.0 during Q1 2022, and its lowest value of $11.0 during Q3 2024.
  • In the last 5 years, iBio's Gains from Sales and Divestitures had a median value of $20409.0 in 2024 and averaged $38242.5.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 9998.77% in 2024, then crashed by 1589.62% in 2025.
  • iBio's Gains from Sales and Divestitures (Quarter) stood at $103003.0 in 2021, then crashed by 91.4% to $8854.0 in 2022, then tumbled by 44.08% to $4951.0 in 2023, then crashed by 99.78% to $11.0 in 2024, then soared by 321436.36% to $35369.0 in 2025.
  • Its Gains from Sales and Divestitures was $35369.0 in Q2 2025, compared to $11575.0 in Q1 2025 and $11.0 in Q4 2024.